Premium
Masitinib monotherapy in canine epitheliotropic lymphoma
Author(s) -
Holtermann N.,
Kiupel M.,
Kessler M.,
Teske E.,
Betz D.,
Hirschberger J.
Publication year - 2016
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12157
Subject(s) - platelet derived growth factor receptor , lymphoma , immunohistochemistry , medicine , canine lymphoma , receptor , growth factor , gastroenterology
This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor ( SCF ). platelet‐derived growth factor ( PDGF )‐ AA was weakly positive in two and negative in six. PDGF‐BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor ( PDGFR )‐β, seven were negative for that receptor. Five showed strong expression of PDGFR ‐α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.